Aurobindo Pharma Limited Vacancies | Vacancy for L&D Professional

· To Develop and institutionalize the Talent Philosophy
· Develop a well-integrated Talent philosophy which cuts across all businesses and attracts the best and high potential talent from the market and industry.
· Build a learning culture within the organization by successfully leveraging technology and creating robust career paths for employees to make informed decisions about their careers.
· To be a strategic partner to the business stakeholders and support people practices which will enable business.
· Understand business strategy and suggest new age people practices which will enable the business performance.
· Support in building Leadership development programs through running effective 360-degree feedback, and assessment centres and identifying best-in-class options for developing future leaders.
· Suggest a learning strategy for the group and create a robust plan for developing functional schools in the organization to build functional capabilities across the group.
· Leverage technology to drive a learning culture within the organization.
· Suggest new-age learning practices to enable businesses.
· Engage resources / third-party providers and internal stakeholders for content development.
· Drive implementation of Leadership competency framework across all the key people processes.
· Track and publish learning dashboards and implement processes for measuring training effectiveness.
Interested candidates with relevant experience can send their profiles to [***]

Aurobindo Pharma Limited is an Indian pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The companys area of activity includes six major therapeutic/product areas: antibiotics, antiretrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergics. The company markets these products in over 125 countries Its marketing partners include AstraZeneca and Pfizer.
Aurobindo Pharma plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars, and novel drug delivery solutions like depot injections, inhalers, patches, and films. It has also set its sights on geographic expansion in new territories like Poland, Italy, Spain, the Czech Republic, Portugal, and France, as the generic drug market in these countries is relatively small.
In 2017, Aurobindo Pharma inked a pact to acquire Portugals Generis Farmaceutica SA from Magnum Capital Partners for a consideration of 135 million. It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.
Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the Netherlands, Spain, and Belgium. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.